TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage company developing novel therapies for treatment of the most aggressive cancers, announced on Monday that it showcased updated results from the NOX-A12 GLORIA Phase 1/2 trial at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona.
Led by Dr Frank A. Giordano, the trial examined the efficacy of combining NOX-A12 with bevacizumab in treating newly diagnosed glioblastoma patients resistant to standard chemotherapy.
The data highlighted a significant improvement in survival rates for patients receiving the NOX-A12 and bevacizumab combination. Compared to standard of care or NOX-A12 alone, the combination therapy resulted in longer median progression-free survival (9.1 months vs. 4.0 months and 5.7 months) and median overall survival (19.9 months vs. 9.5 months and 12.7 months). Additionally, the combination led to a notable decrease in tumor blood flow, reinforcing its mechanism of action.
Titled 'Dual inhibition of postradiogenic angio-vasculogenesis in glioblastoma: Results of the phase 1/2 GLORIA trial', the presentation took place during the mini oral session on CNS tumors. The trial's findings include that two out of six patients in the NOX-A12 and bevacizumab arm survived beyond 26 months.
TME Pharma is advancing the NOX-A12 programme, with ongoing trials evaluating its combination with radiotherapy and other agents. The FDA has approved a randomized Phase 2 trial design and granted fast track designation to NOX-A12. TME Pharma is also exploring the potential of NOX-A12 in metastatic pancreatic cancer through its OPTIMUS study.
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Alume Biosciences names new chief commercial officer
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director